Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown promising results in gastric cancer. We investigated the clinical significance of CLDN18.2 and other cell-adherens junction molecules (Rho GTPase-act...
Saved in:
| Published in | Journal of gastric cancer Vol. 20; no. 4; pp. 408 - 420 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Gastric Cancer Association
01.12.2020
대한위암학회 |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown promising results in gastric cancer. We investigated the clinical significance of CLDN18.2 and other cell-adherens junction molecules (Rho GTPase-activating protein [RhoGAP] and E-cadherin) in metastatic diffuse-type gastric cancer (mDGC).
We evaluated CLDN18.2, RhoGAP, and E-cadherin expression using two-plex immunofluorescence and quantitative data analysis of H-scores of 77 consecutive mDGC patients who received first-line platinum-based chemotherapy between March 2015 and February 2017.
CLDN18.2 and E-cadherin expression was significantly lower in patients with peritoneal metastasis (PM) than those without PM at the time of diagnosis (P=0.010 and 0.013, respectively), whereas it was significantly higher in patients who never developed PM from diagnosis to death than in those who did (P=0.001 and 0.003, respectively). Meanwhile, CLDN18.2 and E-cadherin expression levels were significantly higher in patients with bone metastasis than in those without bone metastasis (P=0.010 and 0.001, respectively). Moreover, we identified a positive correlation between the expression of CLDN18.2 and E-cadherin (P<0.001), RhoGAP and CLDN18.2 (P=0.004), and RhoGAP and E-cadherin (P=0.001). Conversely, CLDN18.2, RhoGAP, and E-cadherin expression was not associated with chemotherapy response and survival.
CLDN18.2 expression was reduced in patients with PM but significantly intact in those with bone metastasis. Furthermore, CLDN18.2 expression was positively correlated with other adherens junction molecules, which is clinically associated with mDGC and PM pathogenesis. |
|---|---|
| AbstractList | Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown promising results in gastric cancer. We investigated the clinical significance of CLDN18.2 and other cell-adherens junction molecules (Rho GTPase-activating protein [RhoGAP] and E-cadherin) in metastatic diffuse-type gastric cancer (mDGC).
We evaluated CLDN18.2, RhoGAP, and E-cadherin expression using two-plex immunofluorescence and quantitative data analysis of H-scores of 77 consecutive mDGC patients who received first-line platinum-based chemotherapy between March 2015 and February 2017.
CLDN18.2 and E-cadherin expression was significantly lower in patients with peritoneal metastasis (PM) than those without PM at the time of diagnosis (P=0.010 and 0.013, respectively), whereas it was significantly higher in patients who never developed PM from diagnosis to death than in those who did (P=0.001 and 0.003, respectively). Meanwhile, CLDN18.2 and E-cadherin expression levels were significantly higher in patients with bone metastasis than in those without bone metastasis (P=0.010 and 0.001, respectively). Moreover, we identified a positive correlation between the expression of CLDN18.2 and E-cadherin (P<0.001), RhoGAP and CLDN18.2 (P=0.004), and RhoGAP and E-cadherin (P=0.001). Conversely, CLDN18.2, RhoGAP, and E-cadherin expression was not associated with chemotherapy response and survival.
CLDN18.2 expression was reduced in patients with PM but significantly intact in those with bone metastasis. Furthermore, CLDN18.2 expression was positively correlated with other adherens junction molecules, which is clinically associated with mDGC and PM pathogenesis. Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown promising results in gastric cancer. We investigated the clinical significance of CLDN18.2 and other cell-adherens junction molecules (Rho GTPase-activating protein [RhoGAP] and E-cadherin) in metastatic diffuse-type gastric cancer (mDGC).PURPOSEIsoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown promising results in gastric cancer. We investigated the clinical significance of CLDN18.2 and other cell-adherens junction molecules (Rho GTPase-activating protein [RhoGAP] and E-cadherin) in metastatic diffuse-type gastric cancer (mDGC).We evaluated CLDN18.2, RhoGAP, and E-cadherin expression using two-plex immunofluorescence and quantitative data analysis of H-scores of 77 consecutive mDGC patients who received first-line platinum-based chemotherapy between March 2015 and February 2017.MATERIALS AND METHODSWe evaluated CLDN18.2, RhoGAP, and E-cadherin expression using two-plex immunofluorescence and quantitative data analysis of H-scores of 77 consecutive mDGC patients who received first-line platinum-based chemotherapy between March 2015 and February 2017.CLDN18.2 and E-cadherin expression was significantly lower in patients with peritoneal metastasis (PM) than those without PM at the time of diagnosis (P=0.010 and 0.013, respectively), whereas it was significantly higher in patients who never developed PM from diagnosis to death than in those who did (P=0.001 and 0.003, respectively). Meanwhile, CLDN18.2 and E-cadherin expression levels were significantly higher in patients with bone metastasis than in those without bone metastasis (P=0.010 and 0.001, respectively). Moreover, we identified a positive correlation between the expression of CLDN18.2 and E-cadherin (P<0.001), RhoGAP and CLDN18.2 (P=0.004), and RhoGAP and E-cadherin (P=0.001). Conversely, CLDN18.2, RhoGAP, and E-cadherin expression was not associated with chemotherapy response and survival.RESULTSCLDN18.2 and E-cadherin expression was significantly lower in patients with peritoneal metastasis (PM) than those without PM at the time of diagnosis (P=0.010 and 0.013, respectively), whereas it was significantly higher in patients who never developed PM from diagnosis to death than in those who did (P=0.001 and 0.003, respectively). Meanwhile, CLDN18.2 and E-cadherin expression levels were significantly higher in patients with bone metastasis than in those without bone metastasis (P=0.010 and 0.001, respectively). Moreover, we identified a positive correlation between the expression of CLDN18.2 and E-cadherin (P<0.001), RhoGAP and CLDN18.2 (P=0.004), and RhoGAP and E-cadherin (P=0.001). Conversely, CLDN18.2, RhoGAP, and E-cadherin expression was not associated with chemotherapy response and survival.CLDN18.2 expression was reduced in patients with PM but significantly intact in those with bone metastasis. Furthermore, CLDN18.2 expression was positively correlated with other adherens junction molecules, which is clinically associated with mDGC and PM pathogenesis.CONCLUSIONSCLDN18.2 expression was reduced in patients with PM but significantly intact in those with bone metastasis. Furthermore, CLDN18.2 expression was positively correlated with other adherens junction molecules, which is clinically associated with mDGC and PM pathogenesis. Purpose: Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown promising results in gastric cancer. We investigated the clinical significance of CLDN18.2 and other cell-adherens junction molecules (Rho GTPase-activating protein [RhoGAP] and E-cadherin) in metastatic diffuse-type gastric cancer (mDGC). Materials and Methods: We evaluated CLDN18.2, RhoGAP, and E-cadherin expression using two-plex immunofluorescence and quantitative data analysis of H-scores of 77 consecutive mDGC patients who received first-line platinum-based chemotherapy between March 2015 and February 2017. Results: CLDN18.2 and E-cadherin expression was significantly lower in patients with peritoneal metastasis (PM) than those without PM at the time of diagnosis (P=0.010 and 0.013, respectively), whereas it was significantly higher in patients who never developed PM from diagnosis to death than in those who did (P=0.001 and 0.003, respectively). Meanwhile, CLDN18.2 and E-cadherin expression levels were significantly higher in patients with bone metastasis than in those without bone metastasis (P=0.010 and 0.001, respectively). Moreover, we identified a positive correlation between the expression of CLDN18.2 and E-cadherin (P<0.001), RhoGAP and CLDN18.2 (P=0.004), and RhoGAP and E-cadherin (P=0.001). Conversely, CLDN18.2, RhoGAP, and E-cadherin expression was not associated with chemotherapy response and survival. Conclusions: CLDN18.2 expression was reduced in patients with PM but significantly intact in those with bone metastasis. Furthermore, CLDN18.2 expression was positively correlated with other adherens junction molecules, which is clinically associated with mDGC and PM pathogenesis. KCI Citation Count: 0 |
| Author | Roh, Sang-Young Shin, Kabsoo Kim, Bohyun Park, Jae Myung Lee, Sung Hak Lee, Han Hong Kim, In-Ho Song, Kyo Yong Kim, Sang-Yeob Seo, Junyoung Kim, Seo Ree Kim, Jeong-Oh |
| AuthorAffiliation | 1 Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 6 Department of Clinical Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 5 Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 9 Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 3 Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 8 Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 10 Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea 2 Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University o |
| AuthorAffiliation_xml | – name: 3 Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 6 Department of Clinical Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 5 Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 9 Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – name: 2 Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 7 Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 4 Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 8 Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – name: 10 Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea – name: 1 Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Seo Ree orcidid: 0000-0001-7461-103X surname: Kim fullname: Kim, Seo Ree organization: Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 2 givenname: Kabsoo orcidid: 0000-0002-6709-0894 surname: Shin fullname: Shin, Kabsoo organization: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 3 givenname: Jae Myung surname: Park fullname: Park, Jae Myung organization: Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 4 givenname: Han Hong orcidid: 0000-0002-7541-8490 surname: Lee fullname: Lee, Han Hong organization: Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 5 givenname: Kyo Yong orcidid: 0000-0002-5840-1638 surname: Song fullname: Song, Kyo Yong organization: Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 6 givenname: Sung Hak surname: Lee fullname: Lee, Sung Hak organization: Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Clinical Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 7 givenname: Bohyun surname: Kim fullname: Kim, Bohyun organization: Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 8 givenname: Sang-Yeob orcidid: 0000-0002-3724-256X surname: Kim fullname: Kim, Sang-Yeob organization: Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – sequence: 9 givenname: Junyoung orcidid: 0000-0003-0723-1891 surname: Seo fullname: Seo, Junyoung organization: Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea – sequence: 10 givenname: Jeong-Oh surname: Kim fullname: Kim, Jeong-Oh organization: Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 11 givenname: Sang-Young surname: Roh fullname: Roh, Sang-Young organization: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea – sequence: 12 givenname: In-Ho orcidid: 0000-0002-0351-2074 surname: Kim fullname: Kim, In-Ho organization: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Department of Gastric Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33425442$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002663984$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1kU1P3DAQhq2KCihw7q3KsT1kcfwRx5dKKFCKtG0lukW9WY4z3hqy9mJnK_j3OCygtlJ9mBmNn3fG8vsG7fjgAaG3FZ5xQvHx9dLMCCY4hxlQ-grtEyxpyWtW7TzXDfm5h45Susb58LqqMNlFe5Qywhkj--iqHZx3Rg_Fd7f0zubSGyiCLdr56deqmZHi7G4dISUXfOF88QVGnUY9OlOcOms3CcrF_RqK89yNudlO-niIXls9JDh6ygfox6ezRfu5nH87v2hP5qVhko4lF70EKWtmua6JlUC7yjaGyr6TNRe6A0x62mEpbc85w6SRUtMe150wfaboAfqwneujVTfGqaDdY14GdRPVyeXiQsmaCkxFZj9u2fWmW0FvwI9RD2od3UrH-0fl3zfe_cpzfishmkqwacD7pwEx3G4gjWrlkoFh0B7CJinCRN1wwhua0Xd_7npZ8vzxGTjeAiaGlCLYF6TCanJXZXfV5G4OKrubFfwfhXGTD2F6rBv-q3sAbmaojg |
| CitedBy_id | crossref_primary_10_1016_j_heliyon_2023_e21338 crossref_primary_10_17116_patol20248606192 crossref_primary_10_1186_s12957_023_03188_2 crossref_primary_10_1080_21688370_2021_1967080 crossref_primary_10_3389_fimmu_2022_885424 crossref_primary_10_3389_fonc_2023_1258347 crossref_primary_10_1038_s41571_024_00874_2 crossref_primary_10_1186_s12964_023_01406_8 crossref_primary_10_3390_jpm11111095 crossref_primary_10_1093_oncolo_oyae238 crossref_primary_10_1200_PO_23_00543 crossref_primary_10_1097_PAI_0000000000001248 crossref_primary_10_1186_s12885_023_10533_x crossref_primary_10_3390_cancers16234049 crossref_primary_10_3390_cancers14020290 crossref_primary_10_1016_j_prp_2024_155628 crossref_primary_10_1159_000526333 crossref_primary_10_1007_s10120_024_01505_6 crossref_primary_10_1186_s12876_023_02843_y |
| Cites_doi | 10.5230/jgc.2019.19.e32 10.1007/s00428-019-02624-7 10.3322/caac.20107 10.1074/jbc.M113.457499 10.1111/apm.1965.64.1.31 10.1038/onc.2010.215 10.1016/j.celrep.2015.06.020 10.1038/nature13480 10.18632/oncotarget.25464 10.1016/j.ejca.2008.10.026 10.1093/annonc/mdw371.06 10.1371/journal.pone.0074757 10.1038/s41467-018-04907-0 10.5230/jgc.2013.13.3.129 10.1186/s13045-017-0473-4 10.1111/cas.13967 10.1159/000127386 10.1111/j.1349-7006.2007.00490.x 10.1016/j.clinimag.2019.03.002 10.1053/j.gastro.2018.08.041 10.21037/jgo.2017.01.10 10.5230/jgc.2016.16.3.131 10.1158/1538-7445.AM2018-4030 10.3390/ijms19082424 10.1007/s10585-019-09987-w 10.1158/1078-0432.CCR-08-1547 10.1038/s41467-018-06747-4 10.1038/nrc822 10.2147/OTT.S154524 10.1083/jcb.148.4.779 10.1371/journal.pone.0160527 10.1186/s12943-015-0387-0 10.4143/crt.2018.331 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020. Korean Gastric Cancer Association. Copyright © 2020. Korean Gastric Cancer Association 2020 Korean Gastric Cancer Association |
| Copyright_xml | – notice: Copyright © 2020. Korean Gastric Cancer Association. – notice: Copyright © 2020. Korean Gastric Cancer Association 2020 Korean Gastric Cancer Association |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.5230/jgc.2020.20.e33 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2093-5641 |
| EndPage | 420 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9637037 PMC7781747 33425442 10_5230_jgc_2020_20_e33 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; grantid: 2018R1C1B6008724 |
| GroupedDBID | 5-W 53G 8JR 8XY 9ZL AAYXX ABDBF ADBBV ADRAZ ALMA_UNASSIGNED_HOLDINGS AOIJS CITATION EF. HYE KQ8 KVFHK M48 OK1 PGMZT RPM NPM 7X8 5PM ACYCR M~E |
| ID | FETCH-LOGICAL-c493t-57d9e9964f5a62f9e3b1f8c39db9657abe02d3b099fd55402899a3d06b7cd39d3 |
| IEDL.DBID | M48 |
| ISSN | 2093-582X |
| IngestDate | Tue Nov 21 21:41:51 EST 2023 Thu Aug 21 18:32:48 EDT 2025 Thu Jul 10 22:54:22 EDT 2025 Thu Apr 03 06:59:45 EDT 2025 Tue Jul 01 02:55:12 EDT 2025 Thu Apr 24 23:12:21 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Cadherins Chemotherapy Gastric cancer Claudin |
| Language | English |
| License | Copyright © 2020. Korean Gastric Cancer Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c493t-57d9e9964f5a62f9e3b1f8c39db9657abe02d3b099fd55402899a3d06b7cd39d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-7541-8490 0000-0002-5840-1638 0000-0002-0351-2074 0000-0003-0723-1891 0000-0002-6709-0894 0000-0001-7461-103X 0000-0002-3724-256X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.5230/jgc.2020.20.e33 |
| PMID | 33425442 |
| PQID | 2476852583 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9637037 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7781747 proquest_miscellaneous_2476852583 pubmed_primary_33425442 crossref_primary_10_5230_jgc_2020_20_e33 crossref_citationtrail_10_5230_jgc_2020_20_e33 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-01 |
| PublicationDateYYYYMMDD | 2020-12-01 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of gastric cancer |
| PublicationTitleAlternate | J Gastric Cancer |
| PublicationYear | 2020 |
| Publisher | The Korean Gastric Cancer Association 대한위암학회 |
| Publisher_xml | – name: The Korean Gastric Cancer Association – name: 대한위암학회 |
| References | Kim (10.5230/jgc.2020.20.e33_ref24) 2019; 51 Lu (10.5230/jgc.2020.20.e33_ref30) 2015; 14 Singh (10.5230/jgc.2020.20.e33_ref33) 2010; 29 Sahin (10.5230/jgc.2020.20.e33_ref38) 2008; 14 Nakayama (10.5230/jgc.2020.20.e33_ref13) 2019; 110 Matsuda (10.5230/jgc.2020.20.e33_ref19) 2007; 98 Skálová (10.5230/jgc.2020.20.e33_ref34) 2019; 18 Korivi (10.5230/jgc.2020.20.e33_ref7) 2019; 56 Schuler (10.5230/jgc.2020.20.e33_ref22) 2016; 27 Yao (10.5230/jgc.2020.20.e33_ref18) 2015; 12 Cancer Genome Atlas Research Network (10.5230/jgc.2020.20.e33_ref17) 2014; 513 Lauren (10.5230/jgc.2020.20.e33_ref4) 1965; 64 Hazan (10.5230/jgc.2020.20.e33_ref32) 2000; 148 Sun (10.5230/jgc.2020.20.e33_ref9) 2017; 14 Eisenhauer (10.5230/jgc.2020.20.e33_ref23) 2009; 45 Guideline Committee of the Korean Gastric Cancer Association (KGCA) (10.5230/jgc.2020.20.e33_ref2) 2019; 19 Information Committee of Korean Gastric Cancer Association (10.5230/jgc.2020.20.e33_ref3) 2016; 16 Shu (10.5230/jgc.2020.20.e33_ref16) 2018; 9 Dottermusch (10.5230/jgc.2020.20.e33_ref20) 2019; 475 Togano (10.5230/jgc.2020.20.e33_ref25) 2018; 78 Liu (10.5230/jgc.2020.20.e33_ref37) 2014; 2014 Wang (10.5230/jgc.2020.20.e33_ref35) 2016; 11 Kim (10.5230/jgc.2020.20.e33_ref28) 2007; 73 Tanaka (10.5230/jgc.2020.20.e33_ref15) 2018; 9 Hagen (10.5230/jgc.2020.20.e33_ref26) 2018; 155 Yonemura (10.5230/jgc.2020.20.e33_ref12) 2000; 6 Paget (10.5230/jgc.2020.20.e33_ref8) 1989; 8 Zhang (10.5230/jgc.2020.20.e33_ref36) 2018; 11 Onken (10.5230/jgc.2020.20.e33_ref29) 2019; 36 Jemal (10.5230/jgc.2020.20.e33_ref1) 2011; 61 Cho (10.5230/jgc.2020.20.e33_ref11) 2013; 13 Thiery (10.5230/jgc.2020.20.e33_ref10) 2002; 2 Oshima (10.5230/jgc.2020.20.e33_ref27) 2013; 8 Yang (10.5230/jgc.2020.20.e33_ref14) 2018; 9 Wu (10.5230/jgc.2020.20.e33_ref31) 2013; 288 Ansari (10.5230/jgc.2020.20.e33_ref6) 2018; 19 Petrelli (10.5230/jgc.2020.20.e33_ref5) 2017; 8 Singh (10.5230/jgc.2020.20.e33_ref21) 2017; 10 |
| References_xml | – volume: 19 start-page: 1 year: 2019 ident: 10.5230/jgc.2020.20.e33_ref2 publication-title: J Gastric Cancer doi: 10.5230/jgc.2019.19.e32 – volume: 475 start-page: 563 year: 2019 ident: 10.5230/jgc.2020.20.e33_ref20 publication-title: Virchows Arch doi: 10.1007/s00428-019-02624-7 – volume: 61 start-page: 69 year: 2011 ident: 10.5230/jgc.2020.20.e33_ref1 publication-title: CA Cancer J Clin doi: 10.3322/caac.20107 – volume: 288 start-page: 12253 year: 2013 ident: 10.5230/jgc.2020.20.e33_ref31 publication-title: J Biol Chem doi: 10.1074/jbc.M113.457499 – volume: 64 start-page: 31 year: 1965 ident: 10.5230/jgc.2020.20.e33_ref4 publication-title: Acta Pathol Microbiol Scand doi: 10.1111/apm.1965.64.1.31 – volume: 29 start-page: 4741 year: 2010 ident: 10.5230/jgc.2020.20.e33_ref33 publication-title: Oncogene doi: 10.1038/onc.2010.215 – volume: 12 start-page: 272 year: 2015 ident: 10.5230/jgc.2020.20.e33_ref18 publication-title: Cell Reports doi: 10.1016/j.celrep.2015.06.020 – volume: 513 start-page: 202 year: 2014 ident: 10.5230/jgc.2020.20.e33_ref17 publication-title: Nature doi: 10.1038/nature13480 – volume: 9 start-page: 29336 year: 2018 ident: 10.5230/jgc.2020.20.e33_ref15 publication-title: Oncotarget doi: 10.18632/oncotarget.25464 – volume: 45 start-page: 228 year: 2009 ident: 10.5230/jgc.2020.20.e33_ref23 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 27 start-page: vi208 issue: Suppl 6 year: 2016 ident: 10.5230/jgc.2020.20.e33_ref22 publication-title: Ann Oncol doi: 10.1093/annonc/mdw371.06 – volume: 8 start-page: e74757 year: 2013 ident: 10.5230/jgc.2020.20.e33_ref27 publication-title: PLoS One doi: 10.1371/journal.pone.0074757 – volume: 9 start-page: 2447 year: 2018 ident: 10.5230/jgc.2020.20.e33_ref16 publication-title: Nat Commun doi: 10.1038/s41467-018-04907-0 – volume: 13 start-page: 129 year: 2013 ident: 10.5230/jgc.2020.20.e33_ref11 publication-title: J Gastric Cancer doi: 10.5230/jgc.2013.13.3.129 – volume: 10 start-page: 105 year: 2017 ident: 10.5230/jgc.2020.20.e33_ref21 publication-title: J Hematol Oncol doi: 10.1186/s13045-017-0473-4 – volume: 110 start-page: 1352 year: 2019 ident: 10.5230/jgc.2020.20.e33_ref13 publication-title: Cancer Sci doi: 10.1111/cas.13967 – volume: 73 start-page: 192 year: 2007 ident: 10.5230/jgc.2020.20.e33_ref28 publication-title: Oncology doi: 10.1159/000127386 – volume: 14 start-page: 6991 year: 2017 ident: 10.5230/jgc.2020.20.e33_ref9 publication-title: Oncol Lett – volume: 98 start-page: 1014 year: 2007 ident: 10.5230/jgc.2020.20.e33_ref19 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2007.00490.x – volume: 56 start-page: 33 year: 2019 ident: 10.5230/jgc.2020.20.e33_ref7 publication-title: Clin Imaging doi: 10.1016/j.clinimag.2019.03.002 – volume: 18 start-page: 3014 year: 2019 ident: 10.5230/jgc.2020.20.e33_ref34 publication-title: Exp Ther Med – volume: 155 start-page: 1852 year: 2018 ident: 10.5230/jgc.2020.20.e33_ref26 publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.08.041 – volume: 8 start-page: 148 year: 2017 ident: 10.5230/jgc.2020.20.e33_ref5 publication-title: J Gastrointest Oncol doi: 10.21037/jgo.2017.01.10 – volume: 16 start-page: 131 year: 2016 ident: 10.5230/jgc.2020.20.e33_ref3 publication-title: J Gastric Cancer doi: 10.5230/jgc.2016.16.3.131 – volume: 78 start-page: 4030 issue: Suppl 6 year: 2018 ident: 10.5230/jgc.2020.20.e33_ref25 publication-title: Cancer Res doi: 10.1158/1538-7445.AM2018-4030 – volume: 8 start-page: 98 year: 1989 ident: 10.5230/jgc.2020.20.e33_ref8 publication-title: Cancer Metastasis Rev – volume: 19 start-page: E2424 year: 2018 ident: 10.5230/jgc.2020.20.e33_ref6 publication-title: Int J Mol Sci doi: 10.3390/ijms19082424 – volume: 36 start-page: 493 year: 2019 ident: 10.5230/jgc.2020.20.e33_ref29 publication-title: Clin Exp Metastasis doi: 10.1007/s10585-019-09987-w – volume: 14 start-page: 7624 year: 2008 ident: 10.5230/jgc.2020.20.e33_ref38 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-1547 – volume: 9 start-page: 4439 year: 2018 ident: 10.5230/jgc.2020.20.e33_ref14 publication-title: Nat Commun doi: 10.1038/s41467-018-06747-4 – volume: 2 start-page: 442 year: 2002 ident: 10.5230/jgc.2020.20.e33_ref10 publication-title: Nat Rev Cancer doi: 10.1038/nrc822 – volume: 6 start-page: 4234 year: 2000 ident: 10.5230/jgc.2020.20.e33_ref12 publication-title: Clin Cancer Res – volume: 11 start-page: 2955 year: 2018 ident: 10.5230/jgc.2020.20.e33_ref36 publication-title: Onco Targets Ther doi: 10.2147/OTT.S154524 – volume: 148 start-page: 779 year: 2000 ident: 10.5230/jgc.2020.20.e33_ref32 publication-title: J Cell Biol doi: 10.1083/jcb.148.4.779 – volume: 11 start-page: e0160527 year: 2016 ident: 10.5230/jgc.2020.20.e33_ref35 publication-title: PLoS One doi: 10.1371/journal.pone.0160527 – volume: 14 start-page: 120 year: 2015 ident: 10.5230/jgc.2020.20.e33_ref30 publication-title: Mol Cancer doi: 10.1186/s12943-015-0387-0 – volume: 2014 start-page: 637308 year: 2014 ident: 10.5230/jgc.2020.20.e33_ref37 publication-title: BioMed Res Int – volume: 51 start-page: 819 year: 2019 ident: 10.5230/jgc.2020.20.e33_ref24 publication-title: Cancer Res Treat doi: 10.4143/crt.2018.331 |
| SSID | ssj0000561102 |
| Score | 2.2980888 |
| Snippet | Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown... Purpose: Isoform 2 of tight junction protein claudin-18 (CLDN18.2) is a potential target for gastric cancer treatment. A treatment targeting CLDN18.2 has shown... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 408 |
| SubjectTerms | Original 일반외과학 |
| Title | Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33425442 https://www.proquest.com/docview/2476852583 https://pubmed.ncbi.nlm.nih.gov/PMC7781747 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002663984 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Gastric Cancer, 2020, 20(4), , pp.408-420 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Nb9MwFLfYkBCXifFZYJNBHLg4tLZjJyeEuo2B6C5Q1JtlO3bJVrmQttL473mvyQpFReLiKIo_kvf88Xt-zu8R8sr1BeDkIrIQuWYy2orBvWfcca-ErFS5DgYzulDnY_lxkk9-hwPqBLjYadphPKlxM8uuf_x8CwMe8GuGe5pvLqfIRcj7kGRBiD1yG5YljaN01GH9luhbwVKHXgUOVjzLCz5pqX521bG1Su2lJu4CoH-fo_xjYTq7Rw46REnftV3gkNwK6T65M-p85g_I1476c0Y_19OEJ4NQ0XQe6fDTycWgyDg9ve6OwyZaJzoKS4v_GdWentQxrhaBobVK31uM8eHpEMs3D8n47PTL8Jx10RSYl6VYslxXZQDrRsbcKh7LINwgFl6UlStVrq0LfV4JB4gxVoAx0ANZWlH1ldO-glziEdlP8xSeEGpdaZ2wEr24UvmBK6oydwI6g46Ca9Uj2Y30jO-oxjHixcyAyYHiNiBug-KGxIC4e-T1psD3lmXj31lfgjrMla8NMmPjdTo3V40B_P_BwHQCU5jukRc32jIwXNAHYlOYrxaGS7Cvcp4XUNHjVnubFoWQSNjGe0Rv6XWTARvcfpLqb2tKbq0LMO300_95uWfkLn5PeybmOdlfNqtwBMhm6Y7XPfZ4veX0C7mQ9ds |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Significance+of+CLDN18.2+Expression+in+Metastatic+Diffuse-Type+Gastric+Cancer&rft.jtitle=Journal+of+gastric+cancer&rft.au=Seo+Ree+Kim&rft.au=Kab+Soo+Shin&rft.au=%EB%B0%95%EC%9E%AC%EB%AA%85&rft.au=%EC%9D%B4%ED%95%9C%ED%99%8D&rft.date=2020-12-01&rft.pub=%EB%8C%80%ED%95%9C%EC%9C%84%EC%95%94%ED%95%99%ED%9A%8C&rft.issn=2093-582X&rft.eissn=2093-5641&rft.spage=408&rft.epage=420&rft_id=info:doi/10.5230%2Fjgc.2020.20.e33&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_9637037 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2093-582X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2093-582X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2093-582X&client=summon |